Efficacy outlook falls short of interim threshold as Teva stops Phase 2 trial in multiple system atrophy
Emrusolmin aims to prevent disease-related protein aggregation, but its trial has now been stopped because of a low probability of meeting the primary efficacy endpoint. The interim analysis identified no safety concerns, but the future of the overall development program awaits complete data.